Table 4.

Exposure to rufinamide and risk of CNS adverse events: meta-analysis of fatigue/lethargy

Study characteristics			Rufinamide		Placebo		Risk ratio	Weight
Studynumber	Authors	Year	Events	Total	Events	Total	M-H, Fixed, 95% CI	%
1	Biton et al. [11]	2011	4	176	3	180	1.36 [0.31, 6.01]	6.6
2	Brodie et al. [10]	2009	25	156	13	157	1.94 [1.03, 3.64]	28.9
3	Elger et al. [14]	2010	54	262	21	133	1.31 [0.83, 2.07]	62.2
4	Palhagen et al. [15]	2001	5	25	1	25	5.00 [0.63, 39.79]	2.2
Total events			88	619	38	495	1.57 [1.11, 2.24]	100

Heterogeneity: χ = 2.28, d.f. = 3 (P = 0.52); I² = 0%. Test for overall effect: Z = 2.53 (P = 0.01).